What are the NCCN recommendations for treatment of locally advanced/metastatic bladder cancer in platinum-ineligible with no PD-L1 expression patients??

Updated: Feb 23, 2021
  • Author: Kara N Babaian, MD, FACS; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
  • Print

According to NCCN guidelines, in patients with locally advanced/metastatic bladder cancer who are platinum-ineligible and whose tumors have no PD-L1 expression, preferred first-line regimens are atezolizumab and pembrolizumab. Other options include gemcitabine and gemcitabine/paclitaxel. Patients who are cisplatin-ineligible but carboplatin-eligible should receive carboplatin over immune checkpoint inhibitors in first-line treatment. [1, 150]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!